PExA AB

The National Institute for Occupational Safety and Health (NIOSH), which was PExA’s first customer in the United States 🇺🇸, has placed an order for an upgrade of their PExA 2.0 instrument. The U.S. federal agency NIOSH conducts research and provides recommendations to prevent work-related injuries and illnesses.   Read the full press release via the link below: https://lnkd.in/d4qW6w-H

PExA announces that a scientific study using PExA's technology has won an award at the European Respiratory Society (ERS) congress in Vienna. Jeong-Lim Kim, a researcher at the Sahlgrenska Academy, received the award for her study titled "Phospholipid composition of the respiratory tract lining fluid (RTLF) in subjects with Asthma and COPD." Read the full press release via the link below:👇 https://lnkd.in/dnS5UHmb

PExA is participating for the second consecutive year at the European Respiratory Society (ERS) congress, one of the world’s largest congresses in respiratory medicine, taking place this year in Vienna. Five scientific papers featuring results based on the use of PExA’s technology have been accepted for presentation at the congress. View our ERS2024 invitation: https://lnkd.in/dGaDEnUd Read Press release at PExA website: https://lnkd.in/dERrdJ_u

PExA AB Interim Report January - June 2024 released (in Swedish). Read the full interim report via the link below. 👇🩺 https://lnkd.in/d8ZnCpKx

PExA AB, which has developed world-unique research instruments for collecting biological samples from the small airways, can announce that the Company has received trademark approval and registration for PExA® within the European Union. Read the full press release below / Läs hela pressmeddelandet nedan: 👇🏼 English (Google translated) https://lnkd.in/dcyiSN8F Svenska:  https://lnkd.in/d4rg_xRu

On July 10, PExA AB completed its rights issue. The issue, which was conducted with preferential rights for existing shareholders, was subscribed to 75.4 percent, with over 56 percent of the issue subscribed with preferential rights.   Read the full press release below (In swedish): 👇🏼 https://lnkd.in/dE6Zha85

In a recently published review article, researchers from University Hospital Southampton NHS FT and the University of Southampton evaluate PExA's technology by summarizing results from previous studies using PExA and comparable methods. The measurement of specific biomarkers of airway inflammation obtained directly from the RTLF by PExA enables a more accurate and comprehensive understanding of pathophysiological changes at the molecular level in patients with acute and chronic lung diseases. The article describes how acute and chronic lung diseases are increasing and that PExA can provide unique non-invasive small airway-sampling.   The article titled "Particles in Exhaled Air (PExA): Clinical Uses and Future Implications" is publicly available via the PubMed link: https://lnkd.in/dCGx9GaY   Read the entire press release in the link below. https://lnkd.in/diWriNZq

Happy to announce insightful interviews with PExA AB in Börsvärlden and Stockpicker AB. Read the interviews below to learn more about our journey, innovative approach in lung research and how we are advancing early detection methods. 🫁 📌 Börsvärlden interview: https://lnkd.in/devsyKr3 📌 Stockpicker interview: https://lnkd.in/dU-2H_tQ

Tomas Gustafsson, VD för PExA, presenterade verksamheten och den pågående nyemissionen under Financial Stockholm investerarträff i Stockholm den 24 juni. Se hela presentationen via länken nedan 👇 https://lnkd.in/dx7MSxzW

Today, Monday, June 24, 2024, PExA AB begins its rights issue, offering existing shareholders new shares at 0.35 SEK each. If fully subscribed, it will raise 7.4 MSEK before costs. Read more in the rights issue memorandum to see how you too can become a shareholder in PExA. https://lnkd.in/dtJS2Cfk Read the entire press release in the link below (in Swedish). https://lnkd.in/dt46TRtK